This is a study with large sample size monitoring
M. pneumoniae in hospitalized children with pneumonia. In our study, 71,965 respiratory tract samples were surveyed. In this study, we observed that 14.2% (10206/71965) of hospitalized children with pneumonia were positive for
M. pneumoniae, which was similar to the study in North China (
15) and also comparable with the global incidence of 12% (range 11% - 15%) published by the Atypical Pathogens Reference Laboratory Database (
16). Gao et al. reported the rate of MPP reaching 37.5% in pediatric patients with pneumonia in North China (
17) which is higher than our study. In addition, we also observed that the rate of MPP in peak years increased, reaching to 38.6% in September 2019 (which is not shown in the article).
We used SAT-MP targeting
M. pneumoniae 16s rRNA for detection of
M. pneumoniae. There are two advantages in this method: (1) It has higher sensitivity, because 16s rRNA template is much more than the genome of
M. pneumoniae in one copy of
M. pneumonia (
14,
18); (2) it suggests live
M. pneumoniae infection, SAT-MP targets to 16s rRNA and its half life is much shorter than DNA (
19). Compared with the results of DNA test, SAT-MP can give the true positive result of
M. pneumoniae in early infection stage.
Several studies showed gender was not a risk factor for
M. pneumoniae infection (
20,
21). However, in our surveillance period, the positive rate of
M. pneumoniae pneumonia was higher in girls compared with boys, which was in accordance with our previous study (
22) and the study in North China (
17). It indicated that girls are more susceptible to
M. pneumoniae infection. Previous studies reported that
M. pneumoniae pneumonia varied in occurrence rate over the years, showing an epidemic cycle of 3 - 5 years worldwide and persisted for 1 - 2 years (
23,
24). In our study, we found that in the second half of 2015, the positive rate of
M. pneumoniae reached 24.5%, indicating that 2015 was the year of
M. pneumoniae epidemic. During the first few months of the second half of 2019, the positive rate of
M. pneumoniae showed an upper trend (36.9% in July, 38.5% in August, 38.6% in September and 29.6% in October, not shown in this article), which suggested 2019 may be another year of
M. pneumoniae epidemic. These results were similar to the epidemic patterns of MPP in Korea, with a cycle of 3 - 4 years (
25).
In year-round or apart, summer (June to September) was the peak season for
M. pneumoniae pneumonia in Hangzhou, with the highest occurrence in August. Previous studies also revealed that infections tend to be more common in summer and early autumn. A study in northern China revealed that
M. pneumoniae infection was more frequent between July and November, with the same manifestation among children and adults (
15). Another study in North China showed that autumn (September to November) was the peak season (
17). But Kutty et al., following a two-and-half-year study, found that in the USA,
M. pneumoniae infection was endemic without significant seasonal fluctuations (
26). This may be due to the influence of different climates (
22).
Our study indicated that children older than 5 years, with the incidence over 30%, were the most susceptible population. The findings are similar to many previous studies (
3,
9,
10,
22,
27). However, in our study young children also have a high rate of
M. pneumoniae infection in Hangzhou, with 20.2% among the 3 - 5 year-olds and 11.9% among the 1 - 3 year-olds. The positive rate of
M. pneumoniae was 4.5% in infants. Thus,
M. pneumoniae was considered as a cause for asthma-like exacerbations in young children and infants (
11,
12). The clinical characteristics of positive
M. pneumonia tests in population of infants and young children deserve constant attention in our future research.
5.1. Conclusions
The M. pneumoniae positive rate was higher in older hospitalized children and it had the highest prevalence in summer in Hangzhou. Since this article was defective with the comparatively short study period, in the future studies we will continue to monitor the epidemiological and clinical characteristics of M. pneumoniae and the prognosis of infants infected with M. pneumoniae.